# BFAST (NCT03178552)

> A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: alectinib; atezolizumab; entrectinib
- Indication: advanced or metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03178552
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Alectinib; Atezolizumab; Pemetrexed; Cisplatin; Carboplatin; Gemcitabine; Entrectinib; Cobimetinib; Vemurafenib; Bevacizumab; Divarasib; Docetaxel
- Enrollment: 1000
- Primary outcome: Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
- Primary outcome: Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1
- Primary outcome: Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1
- Primary outcome: Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1
- Primary outcome: Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1
- Primary outcome: Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1
- Primary outcome: Cohort G: Incidence of Adverse Events (AEs)

## Indexed commentary on BFAST so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bfast-nct03178552